11 Jun 2019

Melvyn’s story

In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.

“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.

“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.

“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”

Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.

“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.

“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.

“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”

Professor Francesco Dazzi

“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.

“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”

Related posts

One Cancer Voice writes to Sajid Javid ahead of 10-Year Cancer Plan

1 August 2022

One Cancer Voice writes to Sajid Javid ahead of 10-Year Cancer Plan

Today, with over 50 cancer charities, we wrote to the Secretary of State for Health & Social Care, Sajid Javid, to set out our expectation for next month’s 10-Year Cancer Plan….

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

18 October 2021

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

25 November 2025

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…

Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival

20 September 2021

Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival

Leading UK leukaemia charities Leukaemia Care and Leukaemia UK have announced a new collaboration to increase awareness of the signs and symptoms of leukaemia and drive improvements in the diagnosis of the disease. The campaign, Spot Leukaemia, is running throughout September – Blood Cancer Awareness Month.